Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this research is to design a randomized controlled clinical study, which is based on HLA matching rate to guide tacrolimus regimen. In this study, the possibility of tacrolimus regimen guided by HLA matching rate will be explored, the occurrence rate of GVHD and rejection reaction will be observed, and the occurrence time and degree of adverse reactions caused by immune inhibitors will be identified. In the meantime, providing a possible prospect for prevention of GVHD and reduction or removal of immune inhibitors.
Liver transplantation is the most effective treatment for end-stage liver disease, yet long term survival is limited by acute and chronic rejection reaction and adverse reactions caused by immune inhibitors. However, effective guideline of immune inhibitors regimen after liver transplantation is lacking. Human major histocompatibility antigens (HLA) is crucial in renal transplantation, while the role in liver transplantation is unclear. It is reported that HLA matching was closely related to the occurrence of graft versus host disease (GVHD) after liver transplantation. And by reducing or removing the immune inhibitors can change the course of illness, improve prognosis, at the same time conduce to induce immune tolerance. Therefore, the investigators have the reason to believe that HLA matching rate has closely association with postoperative immune status of patients after liver transplantation, which may guide immune inhibitors regimen. The aim of this research is to design a randomized controlled clinical study, which is based on HLA matching rate to guide tacrolimus regimen. In this study, the possibility of tacrolimus regimen guided by HLA matching rate will be explored, the occurrence rate of GVHD and rejection reaction will be observed, and the occurrence time and degree of adverse reactions caused by immune inhibitors will be identified. In the meantime, providing a possible prospect for prevention of GVHD and reduction or removal of immune inhibitors.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| research group,low MR group | Experimental | tacrolimus regimen guided by HLA matching rate |
|
| observation group,low MR group | No Intervention | tacrolimus regimen is applied according to clinical experience | |
| research group,middle MR group | Experimental | tacrolimus regimen guided by HLA matching rate |
|
| observation group,middle MR group | No Intervention | tacrolimus regimen is applied according to clinical experience | |
| research group,high MR group | Experimental | tacrolimus regimen guided by HLA matching rate |
|
| observation group,high MR group | No Intervention | tacrolimus regimen is applied according to clinical experience |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| tacrolimus regimen guided by HLA matching rate | Other | required low,middle and high tacrolimus concentration in high,middle and low MR group respectively |
|
| Measure | Description | Time Frame |
|---|---|---|
| Possibility of tacrolimus regimen guided by HLA matching rate | Changes of liver function and incidence of acute rejection early after liver transplantation | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence rate of GVHD | Occurrence rate of GVHD between the different groups | 5 years |
| Occurrence time of adverse reactions caused by immune inhibitors | Occurrence time of adverse reactions caused by immune inhibitors between the different groups |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 5 years |
| Degree of adverse reactions caused by immune inhibitors | Degree of adverse reactions caused by immune inhibitors between the different groups | 5 years |
| Patient survival rate | Patient survival rate between the different groups | 1-year,3-year and 5-year |
| ID | Term |
|---|---|
| D006086 | Graft vs Host Disease |
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| ID | Term |
|---|---|
| D007154 | Immune System Diseases |
| D064419 | Chemically-Induced Disorders |
Not provided
Not provided